Logo

CombiMatrix Rebuffed, Hyseq Remains in Favor in Bid for Variangenics

Jan 21, 2003

NEW YORK, Jan. 21 - Hyseq's bid to buy Variagenics is still a go after the attention of another suitor was rebuffed, Variagenics said today.

 

CombiMatrix, owned by Acacia Research Corporation, made an unsolicited merger bid for Variagenics, the company said. The proposal included a stock-for-stock merger.

 

Variagenics board of directors voted down the proposal and reaffirmed their intention of merging with Hyseq, according to the company.

 

Click here for more information.

Breaking News
The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.